PDCD1 and neoplasm: Additionally, it resulted in the reduction of immunosuppressive tumor-associated macrophages of type 2 (TAM2), reversed the immunological tolerance generated by the tumor, increased the infiltration and activation of cytotoxic CD8+ T cells, and enhanced the effectiveness of anti-PD-1 mAb treatment.